HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 68, Number 1, January 02, 2007 Chinese Translation Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Parkinson's disease/Parkinsonism All Clinical trials Clinical trials Randomized controlled (CONSORT agreement) Related Article

A randomized clinical trial of coenzyme Q₁₀ and GPI-1485 in early Parkinson disease

Address correspondence and reprint requests to Dr. Karl Kieburtz, University of Rochester Medical Center, 1351 Mt. Hope Ave., Ste. 223, Rochester, NY 14620; e-mail: Karl.Kieburtz{at}ctcc.rochester.edu

Objective: To determine if future studies of coenzyme Q₁₀ and GPI-1485 in Parkinson disease (PD) may be warranted.

Methods: We conducted a randomized, double-blind, calibrated futility clinical trial of coenzyme Q10 and GPI-1485 in early untreated PD using placebo data from the DATATOP study to establish the futility threshold.

Results: The primary outcome measure (change in total Unified Parkinson’s Disease Rating Scale scores over 1 year) did not meet the prespecified criteria for futility for either agent. Secondary analyses using calibration controls and other more recent placebo data question the appropriateness of the predetermined definition of futility, and suggest that a more restrictive threshold may be needed.

Conclusions: Coenzyme Q₁₀ and GPI-1485 may warrant further study in Parkinson disease, although the data are inconsistent. Additional factors (cost, availability of other agents, more recent data on placebo outcomes, other ongoing trials) should also be considered in the selection of agents for Phase III studies.

*All authors are listed in the appendix.

Sponsored by the NIH (National Institute of Neurological Disorders and Stroke), U01NS043127, U01NS 043128, and U10NS44415 through 4455.

Disclosure: The authors report no conflicts of interest.

Received May 1, 2006. Accepted in final form August 21, 2006.

Related Article

January 2 Highlights
Neurology 2007 68: 4-5. [Full Text] [PDF]

This article has been cited by other articles:

				J. J. Chen and R. Pahwa Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease Journal of Pharmacy Practice, August 1, 2008; 21(4): 244 - 253. [Abstract] [PDF]

				C. Marras and A. Lang Invited Article: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain Neurology, May 20, 2008; 70(21): 1996 - 2003. [Abstract] [Full Text] [PDF]

				B. C. Tilley and W. R. Galpern Screening Potential Therapies: Lessons Learned From New Paradigms Used in Parkinson Disease Stroke, February 1, 2007; 38(2): 800 - 803. [Abstract] [Full Text] [PDF]